Tatva Chintan Pharma Chem Ltd Q4 FY2022 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/c982dvokfxsb8el0kjzmi2i9.pdf

Key Takeaways


SDA: The Temporary Demand Hole

Chintan Shah: "We continue to expect this segment to grow at the most rapid pace. This is just a small hiccup that is on the way because of this unavailability of the key raw materials for the auto industry. Once this is through, then we again are back into a very high growth situation with this product segment."

Flame Retardants: The New Growth Vector

Chintan Shah: "Flame retardant is a huge market potential. So, it runs into few billions of dollars, but we are specifically targeting very niche segments having applications as high purity flame retardants getting into more into the electronics area and into certain specialized electrical applications."

Margins: Cost Pass-Through in Action

Chintan Shah: "Recently, there is a scenario where we have approached a customer just in this current month of April, where certain prices have dropped, and we have approached the customer to reduce the prices accordingly. So, it's a vice versa mechanism that works very well."

Product Pipeline: Broad-Based Commercialisation Underway

SegmentDevelopmentTimeline
SDATwo large customer formal approvals received; commercial supply with first begins Q2 FY23, second from January 2023. Third customer in plant-scale trials, completion expected within 2022.Q2 FY23 onward
PTCCommercial approvals from two MNC customers (one pharma, one agro); commercial usage begins FY23.FY23
Electrolyte SaltsNew customer approval for energy storage devices, awarded commercial supplier opportunity for 2022. Pilot-scale approval underway with another customer.2022
PASCOne product into full commercialisation; another fully approved, supply from Q2. Zeolite-catalyst-based product: samples submitted in 3-4 weeks, commercial supplies in ~18 months.Q2 FY23 / 18 months
MonoglymeContinuous flow development complete; pilot equipment vendor being finalised; plant-scale commercialisation by new technique next financial year. Currently using two-stage dehydration for customer approvals while R&D continues on single-stage.FY24
Metal ExtractionsPlant-scale sample submitted; commercial supplies expected toward Q4 FY23.Q4 FY23
High Purity SubstancesElectrolysis-based ultra-high purity products for semiconductor/electronics space; offered approval opportunity by large MNC. Commercialisation 18-24 months post sample approval. Would be only Indian company in this segment.18-24 months

Capacity & Capex


Other Segments & Green Chemistry


Guidance & Commitments

CommitmentSpecificsTimeline
SDA demand recoverySemiconductor availability to smoothen out; pent-up demand returnsAugust-September 2022
SDA FY23 revenueFlattish versus FY22FY23
Flame retardants commercial productionPlant trials begin June; customer approvals ~4-5 months; ramp-up when new plant availableJune 2022 / November 2022
Flame retardants capacity scale-upGradual ramp to ~5,000 MT/year2-2.5 years
New facility commissioningPlant available for productionDecember 2022 / Q4 FY23
EBITDA marginMaintain within historic range for full year despite product mix changeFY23
Overall FY23 revenue growthSignificant growth rate driven by PTC (~20%), pharma (30-50%), electrolyte salts (4-5x), and new flame retardant revenue, despite flattish SDAFY23
Next capex cyclePlanning to begin, including ~₹75 crore for continuous flow chemistryNext 18-24 months
High purity substances commercialisationPost sample approval18-24 months
Monoglyme plant-scale commercialisationBy new continuous flow techniqueNext financial year (FY24)
Metal extractions commercial supplyToward Q4 FY23
PASC zeolite-catalyst product commercial supply~18 months

Key Metrics

MetricQ4 FY22
Revenue from operations₹98.5 cr, 9% decline QoQ
EBITDA₹22.3 cr, EBITDA margin at 23%
PAT₹17.5 cr, PAT margin at 18%
FY22 revenue from operations₹433.6 cr, growth of 44% YoY
FY22 EBITDA₹117.1 cr, growth of 64% YoY; EBITDA margin 27% vs 24% in FY21
FY22 PAT₹95.9 cr, growth of 83% YoY; PAT margin 22% vs 17% in FY21
SDA revenue growth87% YoY in FY22; Q4 muted due to semiconductor chip shortage
PTC revenue share in Q431% of revenue
SDA revenue share in Q440% of revenue
PASC revenue share in Q427% of revenue
Electrolyte Salts revenue share in Q42.3% of revenue
Exports share74% of revenue in Q4; 79% in FY22
Installed reactor capacity utilization90% in FY22 (294 KL installed)
Installed assembly line utilization64% in FY22 (27 lines installed)
Total workforce471, added 35 permanent employees during FY22
Freight cost as % of revenue7.6% in FY22, up from 3.7% YoY
Fuel cost as % of revenue6.2% in FY22, up from 3% YoY
Packaging cost as % of revenue3.1% in FY22, up from 1.7% YoY
TfS sustainability audit score87%, improved from 78% last year and 54% the year before
SDA FY23 outlookFlattish vs FY22; Q1 and Q2 expected weak, strong demand revival expected from Q3
PTC FY23 growth outlook~20% (normal pace)
PASC (Pharma) FY23 growth outlook~30% to 50%
Electrolyte Salts FY23 growth outlook4–5x of FY22 revenue
Flame retardants initial capacity~80–100 MT/month from existing facility; ramping to ~4,000–5,000 MT/year from Dec 2022
Continuous flow chemistry capex~₹75 cr over next two years
IPO capacity expansion commissioningQ4 FY23, with anticipated 10% cost overrun within budget